Study Finds Lupus Patients Often Stop Treatment

Researchers tracking 124 patients with proliferative lupus nephritis found many discontinued immunosuppressive therapy, with non-adherence linked to higher relapse risk.

Updated on Nov. 17, 2026 in Stroke

Isometric editorial illustration of an open white pill organizer with unlabeled amber capsules spilling onto a slate surface, suggesting medication stopped by patients.
Many patients with proliferative lupus nephritis stopped their immunosuppressive treatment, and those who stopped on their own had an 85.4% five-year relapse risk versus 24.1% for physician-guided stops. AI Illustration. Upload story photo >

A study of 124 patients with first biopsy-proven proliferative lupus nephritis, diagnosed at a French hospital between 2001 and 2022, found that 57.3% discontinued immunosuppressive therapy at least once. The study was published online in Lupus Science & Medicine on November 11, 2026.

Why it matters

Patients who stopped therapy because of non-adherence had a higher renal relapse risk than those withdrawn under physician guidance, with 5-year relapse risk reported at 85.4% versus 24.1%. The findings point to adherence as a key factor in managing this serious kidney complication of lupus.

The study followed 124 patients for a median of 10.1 years, with 43.5% discontinuing therapy by five years and 36.2% of those in remission who stopped experiencing a biopsy-proven relapse. Its median cohort age at diagnosis was 30.8 years, and 88.7% of participants were women.

The players

Lupus Science & Medicine

A peer-reviewed open-access journal that publishes research on lupus and related autoimmune conditions.

The details

Researchers defined discontinuation as the first complete interruption of prescribed drugs lasting longer than the drug-specific interval. Of the stops, 60.6% were guided by physicians for patients in renal remission, while other reasons included adverse events, pregnancy, chronic lesions on repeated biopsy, or unknown causes.

Timeline

  1. 2001 to 2022: Patients were diagnosed at a French hospital during this period.

  2. Median of 39 months: Time on treatment before the first discontinuation.

  3. Median of 19 months: Time before patients who stopped resumed therapy.

  4. November 11, 2026: Study published online in Lupus Science & Medicine.

Health Landscape

The findings add long-term adherence data to the body of lupus nephritis cohort research published in Lupus Science & Medicine. They suggest that treatment withdrawal patterns, rather than only disease biology, shape renal outcomes in this population.

For patients with lupus nephritis, stopping immunosuppressive therapy without medical guidance was associated with substantially higher relapse risk than physician-guided withdrawal. Patients should discuss any plan to reduce or stop medication with their treating physician.

The takeaway

Consistent adherence to immunosuppressive therapy appears to matter for kidney outcomes in lupus nephritis. Decisions to stop treatment are safer when made with a physician.

Further reading

For related coverage of long-term treatment outcomes in chronic conditions, see Stroke.